Kenvue (NYSE:KVUE) Stock Unloaded Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Kenvue stock on March 17th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.

Kenvue Trading Up 0.9%

Shares of KVUE opened at $17.30 on Tuesday. The stock has a fifty day moving average of $17.98 and a two-hundred day moving average of $17.07. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. The company has a market capitalization of $33.15 billion, a PE ratio of 22.46, a price-to-earnings-growth ratio of 3.89 and a beta of 0.61. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The company had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same period in the previous year, the firm posted $0.26 EPS. Kenvue’s revenue was up 3.2% on a year-over-year basis. As a group, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.8%. The ex-dividend date of this dividend was Wednesday, February 11th. Kenvue’s payout ratio is presently 107.79%.

Institutional Investors Weigh In On Kenvue

A number of large investors have recently added to or reduced their stakes in the company. Norges Bank bought a new position in Kenvue during the 4th quarter valued at $756,862,000. Independent Franchise Partners LLP boosted its stake in Kenvue by 56.3% during the 4th quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after acquiring an additional 17,343,785 shares during the last quarter. Sculptor Capital LP boosted its stake in Kenvue by 1,023.5% during the 4th quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock valued at $222,289,000 after acquiring an additional 11,739,328 shares during the last quarter. Capitolis Liquid Global Markets LLC boosted its stake in Kenvue by 1,116.8% during the 4th quarter. Capitolis Liquid Global Markets LLC now owns 10,950,999 shares of the company’s stock valued at $188,905,000 after acquiring an additional 10,050,999 shares during the last quarter. Finally, Cibc World Markets Corp bought a new position in shares of Kenvue in the 4th quarter worth about $162,193,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on KVUE shares. Argus raised shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Citigroup increased their price target on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. UBS Group increased their price target on shares of Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Barclays increased their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Friday, March 6th. Finally, Jefferies Financial Group downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Three analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.58.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.